Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for Wiskott-Aldrich syndrome (WAS). The survival rates of transplanted WAS patients using a matched related (MRD) or unrelated donor (MUD) range from 80 to 90%. Without HSCT, the median life expectancy is 15 years. 1 However, the probability of finding a MRD or MUD is only 30 to 60%. Therefore, an alternative related, haploidentical donor should be considered for the patient who lacks a suitable matched donor. From the previous report, haploidentical HSCT in WAS patients yielded an unfavorable outcome. 1 Currently, a haploidentical HSCT (haplo-HSCT) protocol using post-transplant cyclophosphamide (PT-Cy) for GvHD prophylaxis provides a more favorable outcome in patients with malignant and nonmalignant diseases. 2 To the best of our knowledge, we herein report the first successful haplo-HSCT using PT-Cy in a WAS patient.
The patient was the first male term infant of a non-consanguineous family. He presented with generalized petechiae and intracranial hemorrhage. Initial investigation revealed a platelet count of 16.0 × 10 9 /L and mean platelet volume of 6.6 fL. His thrombocytopenia required platelet transfusions at least twice a week. At the age of 2 months, he developed generalized eczema. He also had viral pneumonia and viral meningitis when 3 months old. Subsequently, he developed autoimmune hemolytic anemia and was treated with prednisolone. His . T-cell proliferation in response to phytohemagglutinin mitogen stimulation was normal. Ig levels were within normal range for his age. A WAS gene mutation at exon 10 (c.1093delG) was detected.
Since he was the only child in his family and there was no potential HLA-MUD available, we decided to perform a haplo-HSCT at the age of 6 months. The patient's HLA typing was: A 02:03,11; B 15:25:01,46; C 01,04:03/06; DRB1 09:01,12:02:01; DQB1 03:03,05:02, and his mother's HLA typing was: A 02,11; B 46, − ; C 01, − ; DRB1 09:01,14:54; DQB1 03:03,05:02. Screening for donor-specific anti-HLA antibodies was negative. The conditioning regimen consisted of rabbit-anti-thymoglobulin (ATG; Thymoglobulin, Sanofi, Quebec, Canada) 1.5 mg/kg/day for 3 days (day − 12 to day − 10), fludarabine (Flu) 35 mg/m 2 /day for 6 days (day − 7 to day − 2) and busulfan 80 mg/m 2 /day for 4 days (day − 7 to day − 4). PBSC (12.8 × 10 6 CD34 + cells/kg) were transfused on day 0. We decided to use PBSC from his mother since this was the decision of the family. Prophylaxis against acute GvHD consisted of cyclophosphamide (50 mg/kg/day) given for 2 days (days +3 and +4), and together with cylcosporin (CSA) and mycophenolate mofetil (MMF) starting on day +5. MMF was discontinued on day +60. This novel conditioning regimen was modified from our previous report in thalassemia patients. 3 We omitted pre-transplant immunosuppression, two cycles of Flu and dexamethasone, which has been used in a previous report since it is felt unnecessary to include this for patients with immunodeficiency syndromes, such as WAS.
There were no toxic effects related to the regimen aside from fever in conjunction with the administration of ATG and with the PBSC infusion. Neutrophil engraftment was noted on day +16 and platelet engraftment on day +22. The peripheral blood-nucleated cell chimerism showed 100% on day 28 and remained 100% at the time of report. He developed grade 1 acute skin GvHD that resolved with prednisolone. CMV reactivation tested by DNA viral load was detected on day 40. The patient received IV ganciclovir for 3 weeks until his CMV viral load was undetectable by PCR. At 7 months post HSCT, he developed bronchiolitis obliterans syndrome. He was treated with an inhaled corticosteroid, oral prednisolone and azithromycin, and the problem improved in about 1 month. At the present time, 13 months post HSCT, he is well engrafted, and shows no sign of WAS. His growth parameters are nearly comparable to those in healthy, age-matched children. No serious infection or viral reactivation has been encountered. The eczema resolved without recurrence. He has not required any further immunosuppressive agents beyond the initial taper of MMF and cyclosporine. Serial follow-up platelet and lymphocyte counts, including lymphocyte subsets, are shown in Figure 1 . Ig levels have remained within normal range. WAS is a rare genetic disorder caused by mutation of the WAS gene on the X chromosome. This mutation results in a defect of actin polymerization in hematopoietic cells, which causes a wide-ranging spectrum of disease. Classic WAS is characterized by triad of primary immunodeficiency, eczema and microthrombocytopenia. 4 The result of HSCT with haploidentical donors in WAS patients is associated with a high risk of graft failure, poor immune reconstitution and a high rate of serious complications, resulting in a lower survival rate when compared with MRD and MUD HSCT. 5, 6 Recently, a case report of a WAS patient transplanted with a haploidentical donor using T-cell depletion (T-cell alpha beta receptor and CD19 depletion) yielded a favorable outcome. 7 However, to our knowledge, there is only one case report of haplo-HSCT with PT-Cy in a SCID patient. 8 The benefits of haplo-HSCT with PT-Cy are selective suppression of the alloreactive T-cells in the graft, which can reduce GvHD and preserve T-regulatory and memory cells, facilitating successful engraftment. 9 Our patient showed relatively rapid and continuous platelet increments as well as immune reconstitution. The lymphocyte count exceeded 1000/mm 3 and the naive T-cells (CD45RA + ) exceeded 30% of the total T-cells at 3 months post HSCT. All subsets of lymphocytes increased gradually and reached a normal range at 1 year post HSCT. Post-transplant CMV reactivation was detected at 1 month after transplant, but the CMV viremia was quickly suppressed with ganciclovir. This could be explained by fast immune reconstitution, especially by T-cell subsets. The additional advantage of this approach compared with T-cell depletion is lower cost. Further studies of additional patients and longer follow-up are needed to fully evaluate the medical benefit, risks and overall cost-effectiveness of this approach, and also including patients with other primary immunodeficiency disorders.
